IVF

INVO Fertility, Inc. (IVF) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. INVO Fertility, Inc. is a healthcare services and technology company focused on the fertility marketplace, operating through two primary segments: Fertility Clinic Services (owning and operating clinics) and INVOcell Device (manufacturing and selling its proprietary intravaginal culture device). The company divested its Therapeutics segment (NAYA Therapeutics) in Q2 2025, which is now reported as discontinued operations.

Key Financial Metrics

Note: Q1 2025 Net Loss includes a $15.9 million loss from discontinued operations related to the NAYA Therapeutics divestiture.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 23% ($0.38 million) year-over-year, driven by organic growth at the Georgia Joint Venture and the addition of the newly acquired Family Beginnings clinic in Indiana.
• Operating Expenses: Selling, General, and Administrative (SG&A) expenses rose 40% to $2.18 million, attributed to increased professional fees, personnel costs, and stock-based compensation ($0.17 million).
• Non-Cash Losses: The Q1 2026 net loss was significantly impacted by a $3.79 million loss on changes in fair value of warrant liability. This resulted from the remeasurement of liability-classified warrants immediately prior to their reclassification to equity following shareholder approval of an authorized share increase.
• Liquidity Improvement: Cash balances increased by $2.83 million to $4.9 million, primarily due to $7.1 million in net proceeds from a warrant inducement exercise in January 2026.
• Capital Structure: The company completed a 1-for-5 reverse stock split in March 2026 and converted all outstanding Series C-2 Preferred Stock to common stock.

Guidance, Outlook, and Risks

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. The company relies on continued access to capital and clinic revenue growth to fund operations.
• Strategic Focus: The company plans to grow clinic revenue organically and pursue additional profitable fertility clinic acquisitions. It aims to reach cash flow break-even through scale.
• Recent Acquisitions: On February 18, 2026, the company acquired Family Beginnings P.C. (Indiana Clinic) for $760,000 (cash and Series D Preferred Stock).
• Regulatory Compliance: The company received letters from Nasdaq regarding late filings of its 10-K and 10-Q. While the 10-K was filed on June 2, 2026, the company remains non-compliant with the Timely Filing Rule until the 10-Q is filed. A plan to regain compliance has been submitted.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses including limited segregation of duties and a lack of adequate accounting resources for complex transactions.
• Debt Obligations: The company has related party notes (JAG Notes) with a principal balance of $660,000 and a Revenue Loan and Security Agreement with a principal balance of approximately $1.02 million. A subsequent event in May 2026 extended the JAG Notes maturity to December 31, 2026.

Investor Verification Checklist

• Verify the status of the Nasdaq compliance plan and the timeline for regaining full listing compliance.
• Confirm the remediation progress regarding material weaknesses in internal controls over financial reporting.
• Monitor the cash burn rate and the company's ability to secure additional financing given the "substantial doubt" going concern warning.
• Review the integration performance of the newly acquired Family Beginnings clinic and its contribution to revenue.
• Assess the impact of the warrant inducement on future dilution and the terms of the new warrants issued.